Contrasting ContraFect Corporation (CFRX) & its Rivals
ContraFect Corporation (NASDAQ: CFRX) is one of 93 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare ContraFect Corporation to related companies based off the strength of its institutional ownership, earnings, analyst recommendations, risk, valuation, dividends and profitability.
Insider & Institutional Ownership
24.5% of ContraFect Corporation shares are held by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are held by institutional investors. 9.3% of ContraFect Corporation shares are held by company insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares ContraFect Corporation and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|ContraFect Corporation||N/A||-$28.65 million||-1.79|
|ContraFect Corporation Competitors||$220.96 million||$56.99 million||-0.64|
ContraFect Corporation’s competitors have higher revenue and earnings than ContraFect Corporation. ContraFect Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently the more affordable than other companies in its industry.
This is a breakdown of current ratings and recommmendations for ContraFect Corporation and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|ContraFect Corporation Competitors||161||542||1199||16||2.56|
ContraFect Corporation presently has a consensus price target of $5.00, indicating a potential upside of 471.43%. All “Biotechnology” companies have a potential upside of 56.83%. Given ContraFect Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe ContraFect Corporation is more favorable than its competitors.
This table compares ContraFect Corporation and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|ContraFect Corporation Competitors||-917.28%||-186.99%||-24.41%|
Volatility & Risk
ContraFect Corporation has a beta of -0.86, suggesting that its stock price is 186% less volatile than the S&P 500. Comparatively, ContraFect Corporation’s competitors have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
ContraFect Corporation competitors beat ContraFect Corporation on 7 of the 12 factors compared.
ContraFect Corporation Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with MarketBeat.com's FREE daily email newsletter.